<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1665-5044</journal-id>
<journal-title><![CDATA[Revista mexicana de neurociencia]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. mex. neurocienc.]]></abbrev-journal-title>
<issn>1665-5044</issn>
<publisher>
<publisher-name><![CDATA[Academia Mexicana de Neurología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1665-50442020000200066</article-id>
<article-id pub-id-type="doi">10.24875/rmn.19000144</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[A multidisciplinary clinic for amyotrophic lateral sclerosis patients in Northeast Mexico]]></article-title>
<article-title xml:lang="es"><![CDATA[Clínica multidisciplinaria para pacientes con esclerosis lateral amiotrófica en el Noreste de México]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[Hector R.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Figueroa-Sánchez]]></surname>
<given-names><![CDATA[Jose A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cantú-Martínez]]></surname>
<given-names><![CDATA[Leonel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Caraza]]></surname>
<given-names><![CDATA[Ricardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Maza]]></surname>
<given-names><![CDATA[Manuel de la]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Escamilla-Garza]]></surname>
<given-names><![CDATA[Juan M.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Valero-Gómez]]></surname>
<given-names><![CDATA[Javier]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Tecnológico y de Estudios Superiores de Monterrey School of Medicine and Health Sciences ]]></institution>
<addr-line><![CDATA[Monterrey Nuevo León]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2020</year>
</pub-date>
<volume>21</volume>
<numero>2</numero>
<fpage>66</fpage>
<lpage>70</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1665-50442020000200066&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1665-50442020000200066&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1665-50442020000200066&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Amyotrophic lateral sclerosis (ALS) is a late-onset neurodegenerative disorder characterized by rapid deterioration and selective death of motor neurons (MNs) in central nervous system. There is no effective therapy for ALS patients. Riluzole, only slightly delays disease progression. Edaravone was FDA approved as an intravenous therapy, however, this drug is expensive and has been applied in few cases in our country. There is compelling evidence patients who attend an ALS multidisciplinary clinic experience improved survival. An ALS multidisciplinary clinic was launched in our institution and adapted to our healthcare system. It is described the processes involved in the evaluation of patients in an all day long session where ALS patients are evaluated by several professionals from different specialties specially trained in the needs of subjects living with this disorder. We consider that this model of healthcare for patients with ALS may be useful in another healthcare institutions in our country.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen Esclerosis Lateral Amiotrófica (ELA) es una enfermedad neurodegenerativa caracterizada por rápido deterioro y muerte selectiva de neuronas motoras en el sistema nervioso central. No existe tratamiento efectivo para los pacientes con ELA. El Riluzole solo prolonga discretamente la sobrevida. El Edaravone aprobado por la FDA como tratamiento intravenoso, es costoso y solo ha sido utilizado en algunos pacientes en nuestro país. Existe evidencia en los últimos años que el manejo multidisciplinario de los pacientes con ELA mejora la sobrevida. En nuestra institución efectuamos la apertura de la clínica multidisciplinaria para ELA. Describimos los procesos involucrados en la evaluación de los pacientes en una sesión durante todo un día, donde los pacientes son evaluados por médicos de diferentes especialidades y con entrenamiento en la evaluación de pacientes con ELA Consideramos que este modelo de atención para el cuidado de los pacientes que sufren este trastorno neurológico es útil y podría ser aplicado en otras instituciones del sector salud de nuestro país.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Amyotrophic lateral sclerosis]]></kwd>
<kwd lng="en"><![CDATA[Multidisciplinary clinic]]></kwd>
<kwd lng="en"><![CDATA[Mortality]]></kwd>
<kwd lng="en"><![CDATA[Survival]]></kwd>
<kwd lng="es"><![CDATA[Esclerosis lateral amiotrófica]]></kwd>
<kwd lng="es"><![CDATA[Clínica multidisciplinaria]]></kwd>
<kwd lng="es"><![CDATA[Mortalidad]]></kwd>
<kwd lng="es"><![CDATA[Sobrevida]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mills]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The natural history of central motor abnormalities in amyotrophic lateral sclerosis]]></article-title>
<source><![CDATA[Brain]]></source>
<year>2003</year>
<volume>126</volume>
<page-range>2558-66</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ringel]]></surname>
<given-names><![CDATA[SP]]></given-names>
</name>
<name>
<surname><![CDATA[Murphy]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Alderson]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The natural history of amyotrophic lateral sclerosis]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>1993</year>
<volume>43</volume>
<page-range>1316-22</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ravits]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[La Spada]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ALS motor phenotypes heterogeneity, focality and spread Deconstructing motor neuron degeneration]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2009</year>
<volume>73</volume>
<page-range>805-11</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zoccolella]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Belghi]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Palagano]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Analysis of survival and prognostic factors in amyotrophic lateral sclerosis:a population based study]]></article-title>
<source><![CDATA[J Neurol Neurosurg Psychiatry]]></source>
<year>2008</year>
<volume>79</volume>
<page-range>33-7</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Horton]]></surname>
<given-names><![CDATA[DK]]></given-names>
</name>
<name>
<surname><![CDATA[Mehta]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Antao]]></surname>
<given-names><![CDATA[VC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Quantifying a Nonnotifiable Disease in the United States. The National Amyotrophic Lateral Sclerosis Registry Model]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2014</year>
<volume>312</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1097-8</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martinez]]></surname>
<given-names><![CDATA[HR]]></given-names>
</name>
<name>
<surname><![CDATA[Molina-Lopez]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Cantu-Martinez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Survival and clinical features in Hispanic amyotrophic lateral sclerosis patients]]></article-title>
<source><![CDATA[Amyotroph Lateral Scler]]></source>
<year>2011</year>
<volume>12</volume>
<page-range>199-205</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[HR]]></given-names>
</name>
<name>
<surname><![CDATA[Parada-Garza]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Meza]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Esclerosis lateral amiotrófica Contribución de la neurología mexicana de 1998 ma 2014]]></article-title>
<source><![CDATA[Rev. Mex Neuroci]]></source>
<year>2014</year>
<volume>15</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>355-62</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Traynor]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Alexander]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Corr]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival:a population based study 1996&#8211;2000]]></article-title>
<source><![CDATA[J Neurol Neurosurg Psychiatry]]></source>
<year>2003</year>
<volume>74</volume>
<page-range>1258-61</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rooney]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Byrne]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Heverin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Survival analysis of Irish amyotrophic lateral sclerosis patients diagnosed from 1995&#8211;2010]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2013</year>
<volume>8</volume>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Van den Bergxs]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Kalmijn]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lindeman]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multidisciplinary ALS care improves quality of life in patients with ALS]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2005</year>
<volume>65</volume>
<page-range>1264-7</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hardiman]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[van der Berg]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Edaravone:a new treatment for ALSon the horizon?]]></article-title>
<source><![CDATA[Lancet Neurol]]></source>
<year>2017</year>
<volume>16</volume>
<page-range>490-1</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zoccolella]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Beghi]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Palagano]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ALS multidisciplinary clinic and survival. Results from a population-based study in Southern Italy]]></article-title>
<source><![CDATA[J Neurol]]></source>
<year>2007</year>
<volume>254</volume>
<page-range>1107-12</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Appel]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[First multidisciplinary care clinical for patients with ALS in United States]]></article-title>
<source><![CDATA[Neurological Institute, Methodist Hospital at Houston Texas]]></source>
<year></year>
<publisher-loc><![CDATA[USA ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="">
<source><![CDATA[ALS Association Communications Department]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Appel]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Stewart]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Appel]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Rating Scale for Amyotrophic Lateral Sclerosis:Description and Preliminary Experience]]></article-title>
<source><![CDATA[Ann Neurol]]></source>
<year>1987</year>
<volume>22</volume>
<page-range>328-33</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
